Biology:Durlobactam
From HandWiki
Short description: Medication
 | |
| Clinical data | |
|---|---|
| Routes of administration | Intravenous |
| Drug class | Antibacterial, beta-lactamase inhibitor |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C8H11N3O6S |
| Molar mass | 277.25 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Durlobactam is a beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter[1] It is an analog of avibactam.
The combination therapy sulbactam/durlobactam was approved for medical use in the United States in May 2023.[1]
References
- ↑ 1.0 1.1 "FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria". U.S. Food and Drug Administration (Press release). 24 May 2023. Retrieved 24 May 2023.
This article incorporates text from this source, which is in the public domain.
Further reading
- "Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam". Frontiers in Microbiology 12: 709974. 2021. doi:10.3389/fmicb.2021.709974. PMID 34349751.
- "Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species". Clinical Infectious Diseases 76 (Supplement_2): S194–S201. May 2023. doi:10.1093/cid/ciad095. PMID 37125470.
 |  |
